Defining the role of TORC1/2 in multiple myeloma

Blood

Volumn 118, Issue 26, 2011, Pages 6860-6870

  Maiso, Patricia ^a   Liu, Yi ^b   Morgan, Brittany ^a   Azab, Abdel Kareem ^a   Ren, Pingda ^b   Martin, Michel B ^b   Zhang, Yong ^a   Liu, Yang ^a   Sacco, Antonio ^a   Ngo, Hai ^a   Azab, Feda ^a   Quang, Phong ^a   Rodig, Scott J ^a   Lin, Charles P ^a   Roccaro, Aldo M ^a   Rommel, Christian ^b   Ghobrial, Irene M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Intellikine Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; PROTEIN P53; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BURKITT LYMPHOMA; CARCINOGENESIS; EGR1 GENE; EPSTEIN BARR VIRUS INFECTION; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SPLEEN; SPLEEN CELL;

EID: 84255197263     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-342394     Document Type: Article

References (35)

1. Thoreen CC, Kang SA, Chang JW, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem. 2009;284(12):8023-8032.
2. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene. 2004;23(18):3151-3171. (Pubitemid 38638827)
3. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle. 2003;2(4):339-345.
4. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol. 2009;10(5):307-318.
5. Hoang B, Frost P, Shi Y, et al. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood. 2010;116(22):4560-4568.
6. Descamps G, Pellat-Deceunynck C, Szpak Y, Bataille R, Robillard N, Amiot M. The magnitude of Akt/phosphatidylinositol 3′-kinase proliferatingsignaling is related to CD45 expression in humanmyeloma cells. J Immunol. 2004;173(8):4953-4959. (Pubitemid 39387777)
7. Menu E, Kooijman R, Van Valckenborgh E, et al.Specific roles for the PI3K and the MEK-ERKpathway in IGF-1-stimulated chemotaxis, VEGFsecretion and proliferation of multiple myeloma cells: study in the 5T33MM model. Br J Cancer. 2004;90(5):1076-1083. (Pubitemid 38495831)
8. Zhang J, Choi Y, Mavromatis B, Lichtenstein A, Li W. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway. Oncogene. 2003;22(40):6289-6295. (Pubitemid 37281658)
9. Choi Y, Zhang J, Murga C, et al. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells. Oncogene. 2002;21(34):5289-5300. (Pubitemid 34948140)
10. Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/ insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther. 2005; 4(10):1533-1540. (Pubitemid 41556435)
11. Martin SK, Fitter S, Bong LF, et al. NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells. J Bone Miner Res. 2010;25(10):2126-2137.
12. Peterson TR, Laplante M, Thoreen CC, et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell. 2009;137(5):873-886.
13. Harvey RD, Lonial S. PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. Future Oncol. 2007;3(6):639-647.
14. Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 2009;23(1):10-24.
15. Raje N, Kumar S, Hideshima T, et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood. 2004;104(13):4188-4193. (Pubitemid 39620173)
16. Frost P, Moatamed F, Hoang B, et al. In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood. 2004;104(13):4181-4187. (Pubitemid 39620172)
17. Shi Y, Gera J, Hu L, et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res. 2002;62(17):5027-5034. (Pubitemid 34984430)
18. Strömberg T, Dimberg A, Hammarberg A, et al. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood. 2004;103(8):3138-3147. (Pubitemid 38451692)
19. Francis LK, Alsayed Y, Leleu X, et al. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17- demethoxygeldanamycin has synergistic activity in multiple myeloma. Clin Cancer Res. 2006; 12(22):6826-6835. (Pubitemid 44876853)
20. Feldman ME, Apsel B, Uotila A, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009;7(2):e38.
21. Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta. 2010;1804(3):433-439.
22. Dowling RJ, Pollak M, Sonenberg N. Current status and challenges associated with targeting mTOR for cancer therapy. BioDrugs. 2009;23(2): 77-91.
23. Roccaro AM, Sacco A, Aujay M, et al. Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. Blood. 2010; 115(20):4051-4060.
24. Roccaro AM, Sacco A, Husu EN, et al. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood. 2010;115(3):559-569.
25. Azab AK, Runnels JM, Pitsillides C, et al. The CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009;113(18):4341-4351.
26. Azab AK, Azab F, Blotta S, et al. RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. Blood. 2009;114(3):619-629.
27. Fan AC, Deb-Basu D, Orban MW, et al. Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. Nat Med. 2009;15(5):566-571.
28. Roccaro AM, Leleu X, Sacco A, et al. Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2008;111(9):4752-4763.
29. Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene. 2001;20(42):5991-6000. (Pubitemid 32955041)
30. Janes MR, Limon JJ, So L, et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med. 2010;16(2): 205-213.
31. de la Rubia J, Such E. DEPTOR expression and response to thalidomide: toward a new therapeutic target in multiple myeloma? Leuk Lymphoma. 2010;51(11):1960-1961.
32. Cai H, Das S, Kamimura Y, Long Y, Parent CA, Devreotes PN. Ras-mediated activation of the TORC2-PKB pathway is critical for chemotaxis. J Cell Biol. 2010;190(2):233-245.
33. Charest PG, Shen Z, Lakoduk A, Sasaki AT, Briggs SP, Firtel RA. A Ras signaling complex controls the RasC-TORC2 pathway and directed cell migration. Dev Cell. 2010;18(5):737-749.
34. Kamimura Y, Tang M, Devreotes P. Assays for chemotaxis and chemoattractant-stimulated TorC2 activation and PKB substrate phosphorylation in Dictyostelium. Methods Mol Biol. 2009; 571:255-270.
35. Zhang S, Readinger JA, Dubois W, et al. Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production. Blood. 2011;117(4):1228-1238.